| answer text |
<p>The NHS Long Term Plan, together with other recent initiatives including the Life
Sciences Sector Deal and the 2019 Voluntary Scheme for Branded Medicines Pricing,
describe the Government’s objectives for a health and care system that delivers world
leading patient care and health outcomes.</p><p> </p><p>The Government wants patients
to benefit from effective new drugs and the Voluntary Scheme for Branded Medicines
Pricing and Access agreed between the Department and the branded pharmaceutical industry
commits to align the speed of National Institute for Health and Care Excellence technology
appraisals for non-cancer medicines to the faster timeline for cancer medicines.</p><p>
</p><p>In addition, the Life Sciences Industrial Strategy set out a vision of being
a world-leader in developing and bringing to market innovative medicines to improve
life-chances of United Kingdom patients. It highlighted the importance of evolving
and simplifying the access system for new medicines by implementing, and building
on, the findings of the Accelerated Access Review.</p>
|
|
